



Annual Scientific Meeting 2021

22-23 July, Virtual live feed/ OnDemand

Equity and Innovation in Multidisciplinary Lung Cancer Care



Timing (AEST)

8:30-10:00am

Thursday 22 July, 2021

Registrations

Light refreshments will be served

10:00-10:10am

Welcome

Dr Emily Stone

ASM2021 Conference Convenor

10:10-10:25am

Opening address

Alexandra Gollidge

Patient Research Advocate

10:25-10:55am

Plenary session

Chair: Dr Emily Stone

The Taiwan Lung Cancer Screening in Never-Smoker Trial (TALENT)

Prof Pan Chyr Yang

Department of Internal Medicine & Dean of the National Taiwan University College of Medicine, Taiwan

Keynote address

Chair: Mr Phillip Antippa

Neoadjuvant treatment options in early-stage disease

A/Prof Jay Lee

Division of Thoracic Surgery, UCLA Santa Monica Medical Center, California, USA

Keynote address

Chair: Prof Nick Pavlakis

The potential of proteogenomics to identify lung cancer treatment pathways

Professor Ramaswamy Govindan

Department of Medicine, Oncology Division, Washington University School of Medicine, Missouri, USA

Panel: Prof Ramaswamy Govindan, A/Prof Jay Lee, Prof Nick Pavlakis, Prof Wendy Cooper, Mr Phillip Antippa, Dr Emily Stone

LUNCH

Keynote address

Chair: A/Prof Shalini Vinod

Stereotactic Ablative Body Radiotherapy (SABR) for oligometastatic lung cancer

A/Prof Shankar Siva

Lead, SABR Program, Peter MacCallum Cancer Centre, Melbourne

Oral abstracts session

Chair: TBD

Systematic Review of Neoadjuvant Immunotherapy for Patients with Resectable Non-Small Cell Lung Cancer- Dr Christopher Cao

Acceptability and Feasibility of Lung Cancer Screening in Australia- Dr Rachael Dodd

Treatment burden experienced by patients with lung cancer- Nicole El-Turk

The expression and clinical relevance of Schlafen-11 and MGMT as a combined biomarker in patients with malignant pleural mesothelioma- Dr Helen Ke

A systematic review into the radiological features predicting local recurrence after SABR in patients with NSCLC- Dr Katherine Lee

Generalisability of Phase III Immunotherapy Trials in Advanced Lung Cancer to Real-World Patients- Dr Monica Tang

Emphysema as a 'Radiomic-Biomarker' Using Low-Dose Computed Tomography Scans in High-Risk Smokers in an Australian Cohort- Dr Katrina Tonga

AFTERNOON TEA

Updates in precision medicine

Chair: Prof Ben Solomon

Prof Nick Pavlakis

TOGA 19/003 ASPIRATION - Prof Nick Pavlakis

TOGA 16/005 OSCILLATE- Prof Ben Solomon

TOGA 16/007 ALKTERNATE- Dr Malinda Itchins

TOGA 16/009 ILLUMINATE- A/Prof Chee Lee

TOGA-Endorsed Clinical Trials

Chair: Dr Malinda Itchins

TOGA 20/006 COGNITION- Dr Maria Aslam

TOGA 18/002 TROG 17.02 OUTRUN- A/Prof Chee Lee

TOGA 16/013 ANZ LCNF Activities and influence of the specialist lung cancer nurse-Dr Vanessa Brunelli

TOGA 21/001 CHEST-RT - A/Prof Paul Mitchell

TOGA 21/002 LUCAP - Prof Fraser Brims

TOGA 21/003 Lung cancer screening implementation - Dr Nicole Rankin



10:55-11:20am

Keynote address

Chair: Mr Phillip Antippa

Neoadjuvant treatment options in early-stage disease

A/Prof Jay Lee

Division of Thoracic Surgery, UCLA Santa Monica Medical Center, California, USA

Keynote address

Chair: Prof Nick Pavlakis

The potential of proteogenomics to identify lung cancer treatment pathways

Professor Ramaswamy Govindan

Department of Medicine, Oncology Division, Washington University School of Medicine, Missouri, USA

Panel: Prof Ramaswamy Govindan, A/Prof Jay Lee, Prof Nick Pavlakis, Prof Wendy Cooper, Mr Phillip Antippa, Dr Emily Stone

LUNCH

Keynote address

Chair: A/Prof Shalini Vinod

Stereotactic Ablative Body Radiotherapy (SABR) for oligometastatic lung cancer

A/Prof Shankar Siva

Lead, SABR Program, Peter MacCallum Cancer Centre, Melbourne

Oral abstracts session

Chair: TBD

Systematic Review of Neoadjuvant Immunotherapy for Patients with Resectable Non-Small Cell Lung Cancer- Dr Christopher Cao

Acceptability and Feasibility of Lung Cancer Screening in Australia- Dr Rachael Dodd

Treatment burden experienced by patients with lung cancer- Nicole El-Turk

The expression and clinical relevance of Schlafen-11 and MGMT as a combined biomarker in patients with malignant pleural mesothelioma- Dr Helen Ke

A systematic review into the radiological features predicting local recurrence after SABR in patients with NSCLC- Dr Katherine Lee

Generalisability of Phase III Immunotherapy Trials in Advanced Lung Cancer to Real-World Patients- Dr Monica Tang

Emphysema as a 'Radiomic-Biomarker' Using Low-Dose Computed Tomography Scans in High-Risk Smokers in an Australian Cohort- Dr Katrina Tonga

AFTERNOON TEA

Updates in precision medicine

Chair: Prof Ben Solomon

Prof Nick Pavlakis

TOGA 19/003 ASPIRATION - Prof Nick Pavlakis

TOGA 16/005 OSCILLATE- Prof Ben Solomon

TOGA 16/007 ALKTERNATE- Dr Malinda Itchins

TOGA 16/009 ILLUMINATE- A/Prof Chee Lee

TOGA-Endorsed Clinical Trials

Chair: Dr Malinda Itchins

TOGA 20/006 COGNITION- Dr Maria Aslam

TOGA 18/002 TROG 17.02 OUTRUN- A/Prof Chee Lee

TOGA 16/013 ANZ LCNF Activities and influence of the specialist lung cancer nurse-Dr Vanessa Brunelli

TOGA 21/001 CHEST-RT - A/Prof Paul Mitchell

TOGA 21/002 LUCAP - Prof Fraser Brims

TOGA 21/003 Lung cancer screening implementation - Dr Nicole Rankin



11:45-12:05pm

Keynote address

Chair: Mr Phillip Antippa

Neoadjuvant treatment options in early-stage disease

A/Prof Jay Lee

Division of Thoracic Surgery, UCLA Santa Monica Medical Center, California, USA

Keynote address

Chair: Prof Nick Pavlakis

The potential of proteogenomics to identify lung cancer treatment pathways

Professor Ramaswamy Govindan

Department of Medicine, Oncology Division, Washington University School of Medicine, Missouri, USA

Panel: Prof Ramaswamy Govindan, A/Prof Jay Lee, Prof Nick Pavlakis, Prof Wendy Cooper, Mr Phillip Antippa, Dr Emily Stone

LUNCH

Keynote address

Chair: A/Prof Shalini Vinod

Stereotactic Ablative Body Radiotherapy (SABR) for oligometastatic lung cancer

A/Prof Shankar Siva

Lead, SABR Program, Peter MacCallum Cancer Centre, Melbourne

Oral abstracts session

Chair: TBD

Systematic Review of Neoadjuvant Immunotherapy for Patients with Resectable Non-Small Cell Lung Cancer- Dr Christopher Cao

Acceptability and Feasibility of Lung Cancer Screening in Australia- Dr Rachael Dodd

Treatment burden experienced by patients with lung cancer- Nicole El-Turk

The expression and clinical relevance of Schlafen-11 and MGMT as a combined biomarker in patients with malignant pleural mesothelioma- Dr Helen Ke

A systematic review into the radiological features predicting local recurrence after SABR in patients with NSCLC- Dr Katherine Lee

Generalisability of Phase III Immunotherapy Trials in Advanced Lung Cancer to Real-World Patients- Dr Monica Tang

Emphysema as a 'Radiomic-Biomarker' Using Low-Dose Computed Tomography Scans in High-Risk Smokers in an Australian Cohort- Dr Katrina Tonga

AFTERNOON TEA

Updates in precision medicine

Chair: Prof Ben Solomon

Prof Nick Pavlakis

TOGA 19/003 ASPIRATION - Prof Nick Pavlakis

TOGA 16/005 OSCILLATE- Prof Ben Solomon

TOGA 16/007 ALKTERNATE- Dr Malinda Itchins

TOGA 16/009 ILLUMINATE- A/Prof Chee Lee

TOGA-Endorsed Clinical Trials

Chair: Dr Malinda Itchins

TOGA 20/006 COGNITION- Dr Maria Aslam

TOGA 18/002 TROG 17.02 OUTRUN- A/Prof Chee Lee

TOGA 16/013 ANZ LCNF Activities and influence of the specialist lung cancer nurse-Dr Vanessa Brunelli

TOGA 21/001 CHEST-RT - A/Prof Paul Mitchell

TOGA 21/002 LUCAP - Prof Fraser Brims

TOGA 21/003 Lung cancer screening implementation - Dr Nicole Rankin



1:30-3:15pm

Keynote address

Chair: Mr Phillip Antippa

Neoadjuvant treatment options in early-stage disease

A/Prof Jay Lee

Division of Thoracic Surgery, UCLA Santa Monica Medical Center, California, USA

Keynote address

Chair: Prof Nick Pavlakis

The potential of proteogenomics to identify lung cancer treatment pathways

Professor Ramaswamy Govindan

Department of Medicine, Oncology Division, Washington University School of Medicine, Missouri, USA

Panel: Prof Ramaswamy Govindan, A/Prof Jay Lee, Prof Nick Pavlakis, Prof Wendy Cooper, Mr Phillip Antippa, Dr Emily Stone

LUNCH

Keynote address

Chair: A/Prof Shalini Vinod

Stereotactic Ablative Body Radiotherapy (SABR) for oligometastatic lung cancer

A/Prof Shankar Siva

Lead, SABR Program, Peter MacCallum Cancer Centre, Melbourne

Oral abstracts session

Chair: TBD

Systematic Review of Neoadjuvant Immunotherapy for Patients with Resectable Non-Small Cell Lung Cancer- Dr Christopher Cao

Acceptability and Feasibility of Lung Cancer Screening in Australia- Dr Rachael Dodd

Treatment burden experienced by patients with lung cancer- Nicole El-Turk

The expression and clinical relevance of Schlafen-11 and MGMT as a combined biomarker in patients with malignant pleural mesothelioma- Dr Helen Ke

A systematic review into the radiological features predicting local recurrence after SABR in patients with NSCLC- Dr Katherine Lee

Generalisability of Phase III Immunotherapy Trials in Advanced Lung Cancer to Real-World Patients- Dr Monica Tang

Emphysema as a 'Radiomic-Biomarker' Using Low-Dose Computed Tomography Scans in High-Risk Smokers in an Australian Cohort- Dr Katrina Tonga

AFTERNOON TEA

Updates in precision medicine

Chair: Prof Ben Solomon

Prof Nick Pavlakis

TOGA 19/003 ASPIRATION - Prof Nick Pavlakis

TOGA 16/005 OSCILLATE- Prof Ben Solomon

TOGA 16/007 ALKTERNATE- Dr Malinda Itchins

TOGA 16/009 ILLUMINATE- A/Prof Chee Lee

TOGA-Endorsed Clinical Trials

Chair: Dr Malinda Itchins

TOGA 20/006 COGNITION- Dr Maria Aslam

TOGA 18/002 TROG 17.02 OUTRUN- A/Prof Chee Lee

TOGA 16/013 ANZ LCNF Activities and influence of the specialist lung cancer nurse-Dr Vanessa Brunelli

TOGA 21/001 CHEST-RT - A/Prof Paul Mitchell

TOGA 21/002 LUCAP - Prof Fraser Brims

TOGA 21/003 Lung cancer screening implementation - Dr Nicole Rankin



3:15-3:45pm

Keynote address

Chair: Mr Phillip Antippa

Neoadjuvant treatment options in early-stage disease

A/Prof Jay Lee

Division of Thoracic Surgery, UCLA Santa Monica Medical Center, California, USA

Keynote address

Chair: Prof Nick Pavlakis

The potential of proteogenomics to identify lung cancer treatment pathways

Professor Ramaswamy Govindan

Department of Medicine, Oncology Division, Washington University School of Medicine, Missouri, USA

Panel: Prof Ramaswamy Govindan, A/Prof Jay Lee, Prof Nick Pavlakis, Prof Wendy Cooper, Mr Phillip Antippa, Dr Emily Stone

LUNCH

Keynote address

Chair: A/Prof Shalini Vinod

Stereotactic Ablative Body Radiotherapy (SABR) for oligometastatic lung cancer

A/Prof Shankar Siva

Lead, SABR Program, Peter MacCallum Cancer Centre, Melbourne

Oral abstracts session

Chair: TBD

Systematic Review of Neoadjuvant Immunotherapy for Patients with Resectable Non-Small Cell Lung Cancer- Dr Christopher Cao

Acceptability and Feasibility of Lung Cancer Screening in Australia- Dr Rachael Dodd

Treatment burden experienced by patients with lung cancer- Nicole El-Turk

The expression and clinical relevance of Schlafen-11 and MGMT as a combined biomarker in patients with malignant pleural mesothelioma- Dr Helen Ke

A systematic review into the radiological features predicting local recurrence after SABR in patients with NSCLC- Dr Katherine Lee

Generalisability of Phase III Immunotherapy Trials in Advanced Lung Cancer to Real-World Patients- Dr Monica Tang

Emphysema as a 'Radiomic-Biomarker' Using Low-Dose Computed Tomography Scans in High-Risk Smokers in an Australian Cohort- Dr Katrina Tonga

AFTERNOON TEA

Updates in precision medicine

Chair: Prof Ben Solomon

Prof Nick Pavlakis

TOGA 19/003 ASPIRATION - Prof Nick Pavlakis

TOGA 16/005 OSCILLATE- Prof Ben Solomon

TOGA 16/007 ALKTERNATE- Dr Malinda Itchins

TOGA 16/009 ILLUMINATE- A/Prof Chee Lee

TOGA-Endorsed Clinical Trials

Chair: Dr Malinda Itchins

TOGA 20/006 COGNITION- Dr Maria Aslam

TOGA 18/002 TROG 17.02 OUTRUN- A/Prof Chee Lee

TOGA 16/013 ANZ LCNF Activities and influence of the specialist lung cancer nurse-Dr Vanessa Brunelli

TOGA 21/001 CHEST-RT - A/Prof Paul Mitchell

TOGA 21/002 LUCAP - Prof Fraser Brims



Annual Scientific Meeting 2021

22-23 July, Swissotel, Sydney
Virtual live feed/ OnDemand

TOGA
Thoracic Oncology Group Australasia

Equity and Innovation in Multidisciplinary Lung Cancer Care

Timing (AEST)
7:00- 8:00am

Friday 23 July, 2021

Microsatellite Breakfast symposium sponsored by Bristol Myers Squibb

Debate: "Are two immunotherapies better than one in first line lung cancer treatment?"

Chair: Prof Nick Pavlakis

Negative: Dr Melissa Moore, Medical Oncologist, St Vincent's Hospital, Melbourne, Australia

Affirmative: Prof Julie Brahmer, Director of the Thoracic Oncology Program & Professor of Oncology, the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Maryland, USA

Followed by perspectives from the audience

8:00- 8:30am
8:30- 9:30am

Light refreshments

Plenary session

'Gaps' and inequalities in lung cancer care

Chair: Mr Phillip Antippa

What is the lung cancer gap?

Ms Lillian Leigh

Patient Research Advocate, Sydney, Australia

Implementation challenges when addressing inequalities

Dr Nicole Rankin

Senior Research Fellow, Sydney School of Public Health Faculty of Medicine & Health, Sydney

The capacity of the health system to address inequalities

Prof Barbara McPake

Director of Nossal Institute & Chair of Global Health, Melbourne School of Population & Global Health, Melbourne

Panel: Ms Alexandra Gollidge, A/Prof Haryana Dhillon, Ms Abby Fyfe, A/Prof Lou Irving

Practical tools for implementing best practice care and embedding research in lung cancer

Chair: Prof Shalini Vinod

Tissue banking in lung cancer – A/Prof Lucy Morgan

Lung cancer registry – Prof Fraser Brims

Teletrials – Dr Craig Underhill

Smoking Cessation – Prof Chris Paul

MORNING TEA

Patient-reported outcome measures – Dr Adeola Bamgboje-Ayodele

Funding lung cancer nurses – Ms Sara McLaughlin Barrett

RAPID program- Prof David Currow

Immunotherapy in mesothelioma

Chair: Dr Steven Kao

TOGA 18/001 DREAM3R

Prof Anna Nowak, Medical oncologist and Pro Vice Chancellor (Health and Medical Research), University of Western Australia, Perth

TOGA Scientific Committee Update- not open to industry members or representatives

Chair: A/Prof Tom John

TOGA working group research prioritisation and gap analysis

New concepts for presentation

LUNCH

TOGA membership meeting

Prof Nick Pavlakis, Chair, TOGA Board of Directors

TOGA Endorsement policy- Prof Ben Solomon, Scientific Chair, TOGA Board of Directors

MDT Masterclass

Chairs: A/Prof Henry Marshall and Dr Steven Kao

Presenters: Dr Venessa Chin, Dr Jonathon Williamson

Panel: Dr Venessa Chin, A/Prof Lucy Morgan, Ms Helen Westman, Dr Tim Akhurst, A/Prof Michael Franco, Prof Wendy Cooper, Dr Michael Harden, Dr Diane Pascoe

Awards and close

3:45- 4:00pm

